BBOT
BridgeBio Oncology Therapeutics, Inc.
Price Chart
Latest Quote
$7.68
-0.05 (-0.65%)
Current Price
| Previous Close | $7.73 |
| Open | $7.82 |
| Day High | $8.09 |
| Day Low | $7.56 |
| Volume | 555,240 |
Stock Information
| Shares Outstanding | 80.11M |
| Total Debt | $2.64M |
| Cash Equivalents | $252.28M |
| Net Income | $-154.10M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $615.22M |
| EPS (TTM) | $-1.92 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $369.60M |
| Income | $-154.10M |
| Book/sh | $4.65 |
| Cash/sh | $3.15 |
| Employees | 106 |
Financial Ratios
| Quick Ratio | 5.83 |
| Current Ratio | 6.16 |
| Debt/Eq | 0.71 |
Returns & Margins
| ROA | -37.20% |
| ROE | -62.21% |
Ownership
| Insider Ownership | 27.20% |
| Institutional Ownership | 68.86% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -3.59 |
| P/B | 1.65 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $25.11 |
Technical Indicators
| SMA20 | $8.13 |
| SMA50 | $8.43 |
| SMA200 | $10.56 |
| RSI | 31.17 |
| ATR | 0.5154 |
| Shares Float | 35.75M |
| Short Float | 13.58% |
| Short Ratio | 9.73 |
| Volatility | 0.29 |
| Rel Volume | 1.60 |
Performance History
| Week | +7.87% |
| Month | -12.23% |
| Quarter | -13.51% |
| 6 Months | -36.00% |
| YTD | -37.51% |
| Year | -29.02% |
| 10 Years | -24.63% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-17 | $7.68 | 555,240 |
| 2026-06-16 | $7.73 | 551,100 |
| 2026-06-15 | $7.73 | 344,700 |
| 2026-06-12 | $7.75 | 227,600 |
| 2026-06-11 | $7.46 | 285,900 |
| 2026-06-10 | $7.12 | 308,100 |
| 2026-06-09 | $7.26 | 526,200 |
| 2026-06-08 | $7.78 | 206,700 |
| 2026-06-05 | $7.81 | 306,600 |
| 2026-06-04 | $8.23 | 93,700 |
| 2026-06-03 | $8.03 | 174,700 |
| 2026-06-02 | $8.27 | 135,400 |
| 2026-06-01 | $8.55 | 187,900 |
| 2026-05-29 | $8.97 | 246,400 |
| 2026-05-28 | $8.84 | 124,300 |
| 2026-05-27 | $8.53 | 531,800 |
| 2026-05-26 | $8.37 | 416,400 |
| 2026-05-22 | $8.55 | 747,200 |
| 2026-05-21 | $9.11 | 497,300 |
| 2026-05-20 | $8.81 | 461,400 |
| 2026-05-19 | $8.72 | 629,700 |
| 2026-05-18 | $8.75 | 558,900 |
About BridgeBio Oncology Therapeutics, Inc.
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.
đ° Latest News
Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter
Motley Fool âĸ 2026-05-17T18:33:40Z
Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally
Motley Fool âĸ 2026-05-17T18:25:46Z
Erasca Stock Is Up 715%. Hereâs Why One Biotech Fund Still Bought $68 Million More
Motley Fool âĸ 2026-05-17T18:18:17Z
Bicara Stock Is Up 50%, and One Biotech Investor Has Made It a 29% Portfolio Bet
Motley Fool âĸ 2026-05-15T23:02:41Z
Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back
Motley Fool âĸ 2026-05-15T22:56:41Z
Kestra Medical Grew Revenue 63%. One Fund Still Trimmed 351,000 Shares
Motley Fool âĸ 2026-05-15T22:50:53Z
Here Are Mondayâs Top Wall Street Analyst Research Calls: Dell Technologies, BioMarin Pharmaceutical, Disney, HubSpot, Klarna, Oklo, Pitney Bowes, Trade Desk, Wendyâs, and More
24/7 Wall St. âĸ 2026-05-11T11:58:15Z
Lilly tumbles on Foundayoâs shaky week; FDA to issue vouchers for psychedelics
BioPharma Dive âĸ 2026-04-24T10:46:00Z
This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know?
Motley Fool âĸ 2026-03-16T23:56:24Z
This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal
Motley Fool âĸ 2026-03-16T23:33:01Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Revenue | |||
| Total Revenue | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 |
| Expenses | |||
| Total Expenses | $145,819,000 | $80,863,000 | $64,771,000 |
| Other Income Expense | $432,000 | $211,000 | - |
| Other Non Operating Income Expenses | $432,000 | $211,000 | - |
| Net Non Operating Interest Income Expense | $11,343,000 | $6,377,000 | $72,000 |
| Operating Expense | $145,819,000 | $80,863,000 | $64,771,000 |
| General And Administrative Expense | $24,620,000 | $7,756,000 | $8,485,000 |
| Income & Earnings | |||
| Net Income From Continuing Operation Net Minority Interest | $-134,044,000 | $-74,275,000 | $-64,699,000 |
| Net Interest Income | $11,343,000 | $6,377,000 | $72,000 |
| Interest Income | $11,343,000 | $6,377,000 | $72,000 |
| Normalized Income | $-134,044,000 | $-74,275,000 | $-64,699,000 |
| Net Income From Continuing And Discontinued Operation | $-134,044,000 | $-74,275,000 | $-64,699,000 |
| Total Operating Income As Reported | $-145,819,000 | $-80,863,000 | $-64,771,000 |
| Net Income Common Stockholders | $-134,044,000 | $-74,275,000 | $-64,699,000 |
| Net Income | $-134,044,000 | $-74,275,000 | $-64,699,000 |
| Net Income Including Noncontrolling Interests | $-134,044,000 | $-74,275,000 | $-64,699,000 |
| Net Income Continuous Operations | $-134,044,000 | $-74,275,000 | $-64,699,000 |
| Pretax Income | $-134,044,000 | $-74,275,000 | $-64,699,000 |
| Interest Income Non Operating | $11,343,000 | $6,377,000 | $72,000 |
| Operating Income | $-145,819,000 | $-80,863,000 | $-64,771,000 |
| Per Share | |||
| Diluted EPS | $-4.30 | $-0.94 | $-0.82 |
| Basic EPS | $-4.30 | $-0.94 | $-0.82 |
| Other | |||
| Tax Effect Of Unusual Items | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-145,209,000 | $-80,655,000 | $-64,679,000 |
| Reconciled Depreciation | $610,000 | $208,000 | $92,000 |
| EBITDA (Bullshit earnings) | $-145,209,000 | $-80,655,000 | $-64,679,000 |
| EBIT | $-145,819,000 | $-80,863,000 | $-64,771,000 |
| Diluted Average Shares | $31,144,775 | $79,196,710 | $69,985,780 |
| Basic Average Shares | $31,144,775 | $79,196,710 | $79,196,710 |
| Diluted NI Availto Com Stockholders | $-134,044,000 | $-74,275,000 | $-64,699,000 |
| Research And Development | $121,199,000 | $73,107,000 | $56,286,000 |
| Selling General And Administration | $24,620,000 | $7,756,000 | $8,485,000 |
| Other Gand A | $24,620,000 | $7,756,000 | $8,485,000 |
Fetched: 2026-06-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Assets | |||
| Net Tangible Assets | $411,096,000 | $-178,637,000 | $-115,641,000 |
| Total Assets | $448,381,000 | $164,301,000 | $5,942,000 |
| Total Non Current Assets | $15,985,000 | $5,608,000 | $2,005,000 |
| Other Non Current Assets | $12,699,000 | $5,118,000 | $1,409,000 |
| Current Assets | $432,396,000 | $158,693,000 | $3,937,000 |
| Other Current Assets | $6,550,000 | $2,981,000 | $1,964,000 |
| Receivables | $386,000 | $81,000 | $1,723,000 |
| Cash Cash Equivalents And Short Term Investments | $425,460,000 | $155,631,000 | $250,000 |
| Cash And Cash Equivalents | $373,687,000 | $30,851,000 | $250,000 |
| Debt | |||
| Total Debt | $2,766,000 | $0 | - |
| Long Term Debt And Capital Lease Obligation | $2,244,000 | $0 | - |
| Current Debt And Capital Lease Obligation | $522,000 | - | - |
| Liabilities | |||
| Total Liabilities Net Minority Interest | $37,285,000 | $342,938,000 | $121,583,000 |
| Total Non Current Liabilities Net Minority Interest | $2,244,000 | $323,358,000 | $104,808,000 |
| Current Liabilities | $35,041,000 | $19,580,000 | $16,775,000 |
| Payables And Accrued Expenses | $28,773,000 | $12,654,000 | $16,775,000 |
| Payables | $1,908,000 | $3,557,000 | $13,239,000 |
| Accounts Payable | $1,374,000 | $3,074,000 | $575,000 |
| Other Current Liabilities | - | $3,105,000 | - |
| Equity | |||
| Common Stock Equity | $411,096,000 | $-178,637,000 | $-115,641,000 |
| Total Equity Gross Minority Interest | $411,096,000 | $-178,637,000 | $-115,641,000 |
| Stockholders Equity | $411,096,000 | $-178,637,000 | $-115,641,000 |
| Gains Losses Not Affecting Retained Earnings | $16,000 | $348,000 | $0 |
| Other Equity Adjustments | $16,000 | $348,000 | - |
| Retained Earnings | $-356,567,000 | $-222,523,000 | $-148,248,000 |
| Preferred Securities Outside Stock Equity | $0 | $323,358,000 | $104,808,000 |
| Other | |||
| Ordinary Shares Number | $79,991,768 | $79,196,710 | $79,196,710 |
| Share Issued | $79,991,768 | $79,196,710 | $79,196,710 |
| Tangible Book Value | $411,096,000 | $-178,637,000 | $-115,641,000 |
| Invested Capital | $411,096,000 | $-178,637,000 | $-115,641,000 |
| Working Capital | $397,355,000 | $139,113,000 | $-12,838,000 |
| Capital Lease Obligations | $2,766,000 | $0 | - |
| Total Capitalization | $411,096,000 | $-178,637,000 | $-115,641,000 |
| Additional Paid In Capital | $767,639,000 | $43,538,000 | $32,607,000 |
| Capital Stock | $8,000 | $0 | $0 |
| Common Stock | $8,000 | $0 | $0 |
| Long Term Capital Lease Obligation | $2,244,000 | $0 | - |
| Current Capital Lease Obligation | $522,000 | $0 | - |
| Pensionand Other Post Retirement Benefit Plans Current | $5,746,000 | $3,821,000 | $0 |
| Current Accrued Expenses | $26,865,000 | $9,097,000 | $3,536,000 |
| Dueto Related Parties Current | $534,000 | $483,000 | $12,664,000 |
| Net PPE | $3,286,000 | $490,000 | $596,000 |
| Gross PPE | $3,286,000 | $490,000 | - |
| Other Properties | $3,286,000 | $490,000 | - |
| Duefrom Related Parties Current | $386,000 | $81,000 | $1,723,000 |
| Other Short Term Investments | $51,773,000 | $124,780,000 | $0 |
Fetched: 2026-06-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Free Cash Flow | |||
| Free Cash Flow | $-114,500,000 | $-55,076,000 | $-52,493,000 |
| Operating Activities | |||
| Operating Cash Flow | $-113,894,000 | $-55,027,000 | $-52,079,000 |
| Cash Flow From Continuing Operating Activities | $-113,894,000 | $-55,027,000 | $-52,079,000 |
| Investing Activities | |||
| Capital Expenditure | $-606,000 | $-49,000 | $-414,000 |
| Investing Cash Flow | $73,328,000 | $-120,530,000 | $-2,820,000 |
| Cash Flow From Continuing Investing Activities | $73,328,000 | $-120,530,000 | $-2,820,000 |
| Net Other Investing Changes | - | $2,406,000 | $-2,406,000 |
| Financing Activities | |||
| Issuance Of Capital Stock | $22,222,000 | $206,238,000 | $55,124,000 |
| Financing Cash Flow | $383,402,000 | $206,290,000 | $55,124,000 |
| Cash Flow From Continuing Financing Activities | $383,402,000 | $206,290,000 | $55,124,000 |
| Net Other Financing Charges | $361,135,000 | - | - |
| Net Preferred Stock Issuance | $22,222,000 | $205,176,000 | $51,500,000 |
| Preferred Stock Issuance | $22,222,000 | $205,176,000 | $51,500,000 |
| Net Common Stock Issuance | $0 | $1,062,000 | $3,624,000 |
| Common Stock Issuance | $0 | $1,062,000 | $3,624,000 |
| Other | |||
| End Cash Position | $373,819,000 | $30,983,000 | $250,000 |
| Beginning Cash Position | $30,983,000 | $250,000 | $25,000 |
| Changes In Cash | $342,836,000 | $30,733,000 | $225,000 |
| Proceeds From Stock Option Exercised | $45,000 | $52,000 | $0 |
| Net Investment Purchase And Sale | $73,934,000 | $-122,887,000 | $0 |
| Sale Of Investment | $157,859,000 | $31,544,000 | $0 |
| Purchase Of Investment | $-83,925,000 | $-154,431,000 | $0 |
| Net PPE Purchase And Sale | $-606,000 | $-49,000 | $-414,000 |
| Purchase Of PPE | $-606,000 | $-49,000 | $-414,000 |
| Change In Working Capital | $6,433,000 | $15,594,000 | $-3,937,000 |
| Change In Other Working Capital | $-254,000 | $9,434,000 | $-2,556,000 |
| Change In Other Current Liabilities | $-47,000 | $0 | - |
| Change In Other Current Assets | $-7,581,000 | $-3,576,000 | $-1,410,000 |
| Change In Payables And Accrued Expense | $17,732,000 | $10,754,000 | $127,000 |
| Change In Accrued Expense | $19,572,000 | $8,256,000 | $-140,000 |
| Change In Payable | $-1,840,000 | $2,498,000 | $267,000 |
| Change In Account Payable | $-1,840,000 | $2,498,000 | $267,000 |
| Change In Prepaid Assets | $-3,417,000 | $-1,018,000 | $-98,000 |
| Other Non Cash Items | $725,000 | $564,000 | - |
| Stock Based Compensation | $5,873,000 | $4,425,000 | $16,465,000 |
| Unrealized Gain Loss On Investment Securities | $7,769,000 | $0 | - |
| Amortization Of Securities | $-1,260,000 | $-1,543,000 | $0 |
| Depreciation Amortization Depletion | $610,000 | $208,000 | $92,000 |
| Depreciation And Amortization | $610,000 | $208,000 | $92,000 |
| Depreciation | $610,000 | $208,000 | $92,000 |
| Net Income From Continuing Operations | $-134,044,000 | $-74,275,000 | $-64,699,000 |
Fetched: 2026-06-17